Matricelf announced earlier today to the Tel Aviv Stock Exchange that it has reached an important milestone.

For the 1st time, the company was able to manufacture human pluripotent stem cells (iPSC) from peripheral blood cells acceptable for future clinical use.

The cells displayed the expected characteristic qualities of safety, division and differentiation.

This is an important step towards the company’s future ability to manufacture autologous neural implants with the potential of treating people with severe spinal cord injuries.